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Abstract:  
Aim: To test the association between cardiometabolic risk factors and 
subjective sleep quality assessed by the Pittsburgh sleep quality index 
(PSQI), independent of obstructive sleep apnea (OSA) and sleep duration. 
Methods: 573 participants from the Baependi Heart Study, a rural cohort 
from Brazil that completed sleep questionnaires and underwent polygraphy 
for OSA evaluation. Multivariable linear regression analysis tested the 
association between cardiovascular risk factors (outcome variables) and 
sleep quality measured by PSQI, adjusting for OSA and other potential 
confounders (age, sex, race, salary/wage, education, marital status, 
alcohol intake, obesity, smoking, hypertension, and sleep duration).  
Results: The sample mean age was of 43±16y, 66% were female, and mean 
body mass index (BMI) was 26±5 kg/m2. Only 20% were classified as obese 
(BMI ≥30). Fifty percent of participants reported poor sleep quality as 
defined by a PSQI score ≥5. A high PSQI score was significantly 
associated with higher very-low density lipoprotein (VLDL) cholesterol 
levels (beta=0.392, p=0.012) and higher triglyceride levels (beta=0.017, 
p=0.006), even after adjustments, including the apnea-hypopnea index. 
Further adjustments accounting for marital status, alcohol intake, and 
medication use did not change these findings. No significant association 
was observed between PSQI scores and glucose or blood pressure. According 
to PSQI components, sleep disturbances (beta=1.976, p=0.027), sleep 
medication use (beta=1.121, p=0.019), and daytime dysfunction 
(beta=1.290, p=0.024) were significantly associated with higher VLDL 
serum levels. Only the daytime dysfunction domain of the PSQI components 
was significantly associated with higher triglyceride levels (beta=0.066, 
p=0.004).  
Conclusion: Poorer lipid profile was independently associated with poor 
sleep quality, assessed by the PSQI questionnaire, regardless of a normal 
sleep duration and accounting for OSA and socio-economic status.  
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Answer to Reviewers' comments: 
 
Ref.:  No. SLEEP-D-18-00185 
Poor Sleep Quality and Lipid Profile in a Rural Cohort  (The Baependi Heart Study) 
 
Dear Editor and Reviewer, 
 
Thank you for considering this manuscript for publication and for the opportunity for 
improvements and clarification. All comments and suggestions were addressed and below we 
provide point-by-point replies to reviewers’ queries and suggestions. 
 
Reviewer #1:  
 
This manuscript by Reis Geovanni and coworkers reports on an association between poor 
sleep quality and deranged lipid profile in a rural family based cohort (the Baependi Heart 
Study). This cohort was designed to address genetic and environmental influences on CVD 
risk factors. In brief,  a high PSQI score was associated with higher VLDL cholesterol and 
TGs. Glucose and blood pressure were not related with PSQI. The PSQI components sleep 
disturabnces, sleep medication use and daytime dysfunction were signicantly associated 
with higher VLDL. 
 
 
1-The study reports on an interesting association between lipid metabolism and sleep 
disturbances. However, the main critisism relates to the preselected study cohort which 
evidently fails to represent the population at large. This limitation needs to be better 
disussed. Another important limitation is the failure to convincingly address the potential 
confounding influence of socioeconomic factors on sleep disturbances (see below). 
 
Thank you for bringing this into consideration. In Table 1 and Table 2, we showed 
characteristics of the full sample (n= 1,801). As shown, participants included in the analytical 
sample (n= 573) were not so different from participants from the full sample according to many 
characteristics. The test for differences for each covariate showed statistical significance for 
some variables that were included in adjustments. In addition, in order to account for 
confounding factors, we have not only further adjusted for medication, alcohol intake, marital 
status (supplemental data), but also added education level to adjustments, as suggested. Thus, our 
findings now adjust for key socioeconomic and demographic factors, including wage/salary and 
education level, which are two commonly used indicators of socioeconomic status. 
*Revision Notes
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2-The authors assume that the Baependi cohort is well known but this is unfortunately not 
the case. Hence, the cohort needs to be much better described in the current method 
section. The cohort was previously used to study associations related to cardiovascular 
disease. What about the lipid analysis in that context? Were there associations with other 
relevant CVD risk factors? 
 
Thank you again for highlighting the importance of a detailed description of the full sample. We 
added further information in the Methods section (pages 3 and 4). Also, Table 1 and Table 2 
have addressed this issue with newer detailed information on demographics, cardiometabolic 
factors, and sleep. Table 3 presents the regression models and each row represents a unique 
regression model for several CVD risk factors. Outcome variables were lipid profile (LDL, HDL, 
total cholesterol, triglycerides, and cholesterol ratio), glucose (glycated hemoglobin and fasting 
glucose), hypertension (systolic and diastolic blood pressure continuous variables), and obesity.  
 
3-A subgroup of 573 participants were addressed in the current study. Which factors 
determined the selection of this group? Was the investigated subgroup representative of the 
whole study group at large? Mean age was below 50 (range unclear), two thirds female but 
more than 50% reporting a poor sleep quality. If there is a possibility that the selection 
process has influenced the outcome that needs to be discussed. 
 
We only studied individuals with complete sleep questionnaire data AND sleep polygraphy. Our 
sample size is contingent on the fact that the sleep polygraphy protocol was only performed in a 
subset of participants. There was no specific inclusion criteria for the polygraphy protocol and 
individuals where randomly sampled from the total sample. This is described in the revised 
Methods section (Methods section, study cohort, pages 3 and 4). In order to provide readers a 
comparison between the overall sample and the analyzed subset, we added in Table 1 and Table 
2 characteristics of the full sample (n=1,801).  
 
4-What about socioeconomic factors and CVD? Poor socioeconomical conditions have  
been identified as a very strong risk factor for sleep disturbances in other epidemiological 
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cohort studies. What was the rational for the salary cut-offs applied in the current study? 
Also, salaries could be given in USD. It is noted that the salary distribution is indeed very 
skewed. Could you consider an analysis based on e.g. salary quartiles or Quintiles?  
Moreover, do the reported findings only reflect salary? What about family income? 
Approximately one third of participants lived as singles. Has an analysis related to 
educational level been considered? It remains that socioeconomy may be one of the 
strongest predictors in the current analysis and the possibility for this needs to be carefully 
evaluated. 
 
We agree that socioeconomic status (SES) is an important potential confounder. In our analyses, 
we have adjusted for two commonly-used indicators of SES, wage/salary and education level, in 
addition to other sociodemographic variables, such as age, sex, race, smoking status, alcohol 
intake, marital status, and medication. Then, after your suggestion regarding education level, we 
further adjusted our models for education with no changes in findings. Wage/salary is a variable 
gathered by questionnaire. Additionally, we also used wage as quartiles or quintiles as suggested. 
Finally, we have added all categories (as shown in table 1), by minimum wage, into regression 
models (Table 3 footnotes), without changes in findings. We do not believe using a dollar 
conversion rule can be helpful to the overall economic understanding of this sample since, over 
the last decade, it has fluctuated between 1.5 and 4 Real/Dollar. 
 
 
 
5-A total of 11% were on lipid lowering agents and this was statistically adjusted for 
according to the text. How was that adjustment made? Would you consider excluding those 
on medication? Also, hypnotic medication may be better clarified. How was this classified? 
Was an assessemnt of sleep quality made with or without correcting sleep medication? 
 
Thank you for the suggestions. After your suggestion, we added Table 5 in the main manuscript 
showing the restricted analysis, which excludes those taking lipid-lowering medications. The 
findings remained similar. We did not adjust for sleep medication because it is already included 
in PSQI, preventing model inflation due to the collinearity between variables. We did not assess 
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hypnotic medication due to its complexity and overlapping uses with other diseases. We wrote 
this as a limitation of the current analysis (page 11). 
 
6-Finally, the authors are tempted to discuss a causal relationship at several places in the 
manuscript. Clearly, this study design would not allow for such conclusions to be drawn. 
 
We agree.  We have revised our text to avoid suggesting causality and we have discussed this as 
a limitation of this observational study on page 11. In the conclusion, we have added a sentence 
stressing the need for caution and consideration of potential residual confounding. 
 
HIGHLIGHTS 
 
 Poor sleep quality was independently associated with a worse lipid profile, 
specifically higher VLDL and triglycerides, independently of OSA and sleep 
duration. 
 The PSQI component most significantly associated with both high VLDL and 
triglycerides blood levels was daytime dysfunction. 
 Lipid alterations may be early markers of metabolic dysfunction induced by poor 
sleep quality. 
 Poor sleep quality may be an epiphenomenon of other sleep disturbances, beyond 
OSA and sleep duration. 
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ABSTRACT 
 
Aim: To test the association between cardiometabolic risk factors and subjective sleep 
quality assessed by the Pittsburgh sleep quality index (PSQI), independent of 
obstructive sleep apnea (OSA) and sleep duration. 
Methods: 573 participants from the Baependi Heart Study, a rural cohort from Brazil 
that completed sleep questionnaires and underwent polygraphy for OSA evaluation. 
Multivariable linear regression analysis tested the association between cardiovascular 
risk factors (outcome variables) and sleep quality measured by PSQI, adjusting for OSA 
and other potential confounders (age, sex, race, salary/wage, education, marital status, 
alcohol intake, obesity, smoking, hypertension, and sleep duration).  
Results: The sample mean age was of 43±16y, 66% were female, and mean body mass 
index (BMI) was 26±5 kg/m
2
. Only 20% were classified as obese (BMI ≥30). Fifty 
percent of participants reported poor sleep quality as defined by a PSQI score ≥5. A 
high PSQI score was significantly associated with higher very-low density lipoprotein 
(VLDL) cholesterol levels (beta=0.392, p=0.012) and higher triglyceride levels 
(beta=0.017, p=0.006), even after adjustments, including the apnea-hypopnea index. 
Further adjustments accounting for marital status, alcohol intake, and medication use 
did not change these findings. No significant association was observed between PSQI 
scores and glucose or blood pressure. According to PSQI components, sleep 
disturbances (beta=1.976, p=0.027), sleep medication use (beta=1.121, p=0.019), and 
daytime dysfunction (beta=1.290, p=0.024) were significantly associated with higher 
VLDL serum levels. Only the daytime dysfunction domain of the PSQI components 
was significantly associated with higher triglyceride levels (beta=0.066, p=0.004).  
Conclusion: Poorer lipid profile was independently associated with poor sleep quality, 
assessed by the PSQI questionnaire, regardless of a normal sleep duration and 
accounting for OSA and socio-economic status.  
 
Keywords: lipids; sleep quality; PSQI; Pittsburgh Sleep Quality Index; very-low 
density lipoprotein cholesterol; low-density lipoprotein cholesterol; obstructive sleep 
apnea  
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1.0 INTRODUCTION 
        Sleep disturbances have been associated with metabolic dysregulation and may 
contribute to weight gain, obesity, and diabetes. 
1-6
 Obstructive sleep apnea (OSA) is 
known to explain part of this association, but other factors besides OSA are thought to 
also play a role.
7-13
 For example, poor sleep quality has been associated with obesity, 
diabetes and weight gain, 
8, 9, 11, 12 
but few studies have shown these associations in the 
absence of OSA. 
8, 11 
In addition, there is still controversy about the association between 
poor sleep quality and the lipid profile, once a poorer lipid profile has been initially 
associated only with sleep duration, but not with self-reported sleep quality. 
13 
However, 
a worse lipid profile was also independently associated with poor subjective sleep 
quality scores. 
12
 
       The aim of the current study is to test whether there is an independent association 
between subjective sleep quality, assessed by the Pittsburgh sleep quality index (PSQI) 
questionnaire, and cardiometabolic factors, while adjusting for OSA in a sample from 
the general population. 
 
2.0 METHODS 
2.1 Study cohort 
The Baependi Heart Study, now in its 12
th
 year, is a family-based cohort study aimed at 
evaluating genetic and environmental influences on cardiovascular risk factors. 
14, 15 
Baependi is
 
a small rural town in the state of Minas Gerais, Brazil, with very limited 
inward migration.  At baseline, 1691 individuals across 95 families were evaluated. 
Cross-sectional data have been collected for 2,239 participants. 
15
 The current study 
analyzed a subset of participants at the second evaluation period (from 2010 to 2014). 
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All participants in this subset had completed sleep questionnaires (the PSQI and 
Epworth sleepiness scale-ESS) (n=1,801), and underwent OSA evaluation by overnight 
polygraphy (n= 573). We only studied individuals with complete sleep questionnaire 
data and sleep polygraphy. Our sample size is contingent on the fact that the sleep 
polygraphy protocol was only performed in a subset of participants. There was no 
specific inclusion criteria for the polygraphy protocol and all individuals from the total 
sample were invited to participate in the sleep polygraphy protocol. 
The study protocol was approved by the ethics committee of the Hospital das Clinicas, 
University of São Paulo, Brazil, and each subject provided informed written consent 
before participation. 
 
2.2 Covariates 
Anthropometric measures, such as height, weight, waist, hip, and neck circumferences, 
were measured following standardized procedures as previously described.
16
 Body mass 
index (BMI) was calculated from height and weight (kg/m
2
).  Smoking status was 
defined by asking the question: “Have you smoked cigarettes...?” Being possible 
answers: (1) Yes, in the past, but not currently; (2) Yes, and I still smoke; (3) I have 
never smoked. The three choices were thus characterized as (1) former, (2) current, and 
(3) non-smokers, respectively. 
17 
Seated systolic blood pressure (SBP) and diastolic 
blood pressure (DBP) were assessed by one trained examiner. The mean out of three 
measures was used to describe blood pressure at rest. Medication use, alcohol use, 
salary, education level, and marital status were assessed by questionnaires. 
 
2.3 Sleep questionnaires 
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The PSQI is a self-rated questionnaire which assesses sleep quality over the past month. 
Nineteen individual items generate seven component scores: subjective sleep quality, 
habitual sleep efficiency, sleep latency, sleep duration, sleep disturbances, use of 
sleeping medication, and daytime dysfunction. A global PSQI score equal or greater 
than five has been proposed to distinguish between good and poor sleepers. 
18, 19
 
The ESS is a self-administered questionnaire that provides a measurement of daytime 
sleepiness. The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. 
Excessive daytime sleepiness is defined as a score >10. 
20
 
 
2.4 Other sleep measures 
The diagnosis of OSA was made based on a portable type III study (Stardust II; Philips, 
Eindhoven, Netherlands). The overnight sleep monitor was installed by a technician at 
the patient’s home. Briefly, the portable monitor used pulse oximetry, airflow detection 
through nasal cannula pressure, position sensor, heart rate recorded by pulse oximetry, 
and respiratory effort (chest-strap piezoelectric detection). Apneas were classified as 
central (absence of airflow or ≥90% reduction of baseline for ≥10s associated with the 
absence of thoracic and abdominal effort), obstructive (absence of airflow or ≥90% 
reduction of baseline for ≥10s associated with the presence of thoracic and abdominal 
effort), or mixed (absence of airflow or ≥90% reduction of baseline for ≥10s in the 
presence of thoracic and abdominal effort at the end of the event). 
21, 22 
Hypopneas were 
classified as a 30% or more drop in airflow for ≥10s with a 4% decrease in oxygen 
desaturation. 
21, 22 
The apnea hypopnea index (AHI) was assessed by the number of 
respiratory events (apneas and hypopneas) divided by the total sleep recording time. 
The OSA severity was determined according to standard cutoffs as mild (AHI 5-14), 
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moderate (AHI 15-29) or severe (AHI ≥30). 21,  22  More details about the polygraphy 
exam were previously described. 
23
 
Bedtime and sleep duration were self-reported on the PSQI. Sleep efficiency 
information was extracted from the PSQI questionnaire. Data from sleep duration of this 
cohort has been previously published.
14
 
 
2.5 Metabolic risk factors 
Fasting blood glucose, glycated hemoglobin (HbA1c), total cholesterol, lipoprotein 
fractions, and triglycerides were assayed by standard techniques in 12-hour fasting 
blood samples. Serum samples were stored at -80°C prior to analysis. We also tested the 
cholesterol ratio (total cholesterol divided by high-density lipoprotein (HDL) 
cholesterol). 
24, 25
 
 
2.6 Statistical Analysis 
Descriptive analyses are shown as mean ±SD for continuous and percentage for 
categorical variables. Natural log transformation (ln) was used in cases of departure 
from normality. Because triglycerides showed high kurtosis we log transformed this 
variable (ln) while running linear regression analysis. Multivariable linear regression 
analysis was used to test the independent relationship between cardiovascular risk 
factors as outcome variables (lipid/glucose blood levels and blood pressure) and sleep 
quality as a main predictor (assessed by the PSQI), adjusting for age, sex, race, salary 
(monthly), education level, smoking status (never, former, current), BMI, SBP, daytime 
sleepiness (by ESS-continuous score), AHI continuous score, sleep duration, and 
bedtime. Further adjustments were also made for lipid-lowering medication use, blood 
glucose levels, alcohol use, and marital status. We have also run sensitivity analysis 
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excluding those with OSA (AHI ≥15) in order to explore the association between 
cardiometabolic factors and sleep quality independent of OSA. Similarly, we performed 
a restricted analysis for participants who did not use lipid-lowering medication. Sleep 
quality by the PSQI was used as a continuous score, a dichotomous category (cutoff 5), 
and by its seven domains. The final sample size for the current analysis was 573 
participants, who underwent overnight polygraphy and had completed sleep 
questionnaires. We show descriptive data from the full sample (n=1,801) and from 
those used in the present analysis (n=573). We tested whether those included in our 
analytic sample differed significantly from those who did not participate in the 
polygraphy examinations using independent t tests for continuous variables or chi 
squared tests for categorical variables. Missing data were excluded while running 
regression analysis. Data were analyzed by the IBM SPSS statistics software version 18. 
The alpha level of significance was set as <0.05. 
 
3.0 RESULTS 
        Table 1 shows descriptive data from the total and the analytical sample for 
demographics and cardiovascular risk factors. The analytical sample is predominantly 
female (66%), mean age was 43±16y, age range from 18 to 81yo, and mean BMI of 
26±5kg/m
2
. Overweight (BMI between 25 and 30) participants were 30% and only 20% 
were classified as obese subjects (BMI ≥30). Most reported never having smoked and 
not using alcohol. Almost one quarter of the women in the sample was post-menopausal 
and almost 30% of the sample used anti-hypertensive medication. In general, 
cardiovascular risk factors were within normal ranges. The analytical sample showed a 
similar distribution of variables (demographic and cardiometabolic factors) compared to 
the full sample, except for age, sex, race, smoking status, and blood pressure levels. 
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Table 2 shows sleep characteristics according to questionnaires and polygraphy. Fifty 
percent classified their sleep quality as poor by the PSQI, and 34% reported excessive 
daytime sleepiness. OSA, by polygraphy, was shown in 18% of the study sample. Sleep 
efficiency was considered to be normal (>85%) and self-reported sleep duration 
indicated that the majority of them slept more than 6h/night. Self-reported bedtime 
showed a mean bedtime of 22:40. The analytical sample showed a slightly higher 
percentage of participants with poor sleep quality by the PSQI compared to full sample 
participants (50 vs 46%, respectively). Likewise, the analytical sample showed higher 
percentage of participants with excessive daytime sleepiness compared to participants 
from full sample (34 vs 30%, respectively). After testing for independent associations 
between sleep quality and cardiovascular risk factors, only VLDL cholesterol and 
triglyceride levels remained significantly associated with higher PSQI scores (Table 3). 
To explore other potential confounding factors relating poor sleep quality with the lipid 
profile, we further adjusted for lipid-lowering medication use, fasting glucose levels, 
alcohol use, and marital status. Results remained similar (supplemental material-
appendix A1). To test the association between sleep quality and cardiometabolic risk 
variables, independently of OSA, we also performed an analysis only for those with an 
AHI<15, that is, excluding those with moderate-to-severe OSA. The results remained 
statistically significant (Table 4). In addition, we have also run a restricted analysis 
excluding those taking lipid-lowering medication. The findings remained significant 
(Table 5).  
       Furthermore, we evaluated the PSQI by components as main predictors. 
Supplemental material shows all multiple regression analyses testing PSQI components 
association with cardiovascular risk factors. According to PSQI components, we have 
first modeled them as continuous scores, and then, if statistically significant, they were 
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modeled within strata. Higher scores in the daytime dysfunction domain (showed 
overall and within strata) were significantly associated with higher ln (triglycerides) 
levels (p=0.004) (Appendix A2). The sleep disturbances domain (p=0.027), sleep 
medication use domain (p=0.019), and daytime dysfunction domain (p=0.024) were 
significantly associated with higher VLDL blood levels (Appendix A3).  
 
4.0 DISCUSSION 
         Prior evidence supports that sleep duration and quality may be a potentially 
modifiable risk factor for cardiovascular and metabolic disease. We tested for 
associations between cardiometabolic variables and poor sleep quality, assessed by the 
PSQI, controlling for sleep duration and severity of OSA. Our findings showed that (1) 
50% of this rural-based population reported poor sleep quality, even within a normal 
sleep duration range; (2) higher VLDL cholesterol and triglycerides levels were 
associated with higher PSQI score (i.e. worse sleep quality), even after adjusting for 
potential confounders; and (3) the PSQI component most significantly associated with 
both high VLDL and triglyceride blood levels was daytime dysfunction. Importantly, 
our results appear to be independent of OSA as we have not only adjusted for AHI 
(continuous score), but also tested for these associations excluding those with moderate-
to-severe OSA (AHI ≥15) and the results remained statistically significant. Our results 
are in line with the hypothesis that lipid alterations may be early markers of metabolic 
dysfunction induced by poor sleep quality. 
        There are complex mechanisms behind the association between sleep duration and 
cardiovascular risk factors, since both short 
3, 10, 26, 27 
and long sleep duration
 12, 13
 have 
been associated with cardiometabolic alterations. Studies have shown that obesity is 
associated with poor sleep quality, sleep fragmentation, and sleep duration.
3, 4, 7
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However, only few of these studies tested this association in the absence of OSA.
 8, 9, 11 
A higher PSQI score has been associated with larger waist circumferences, BMI, and 
percentage of body fat, as well as with higher serum levels of insulin and glucose. 
28 
Nonetheless, associations between PSQI and lipids (HDL cholesterol and triglycerides) 
have been inconsistent, being reported to be negative, 
28
 and positive. 
29 
In the scenario of the controversy about the association between lipid profile and 
sleep quality, 
28, 29
 the CARDIA study showed that a higher PSQI score was not 
significantly associated with a poorer lipid profile. 
13
 The poorer lipid profile was 
statistically associated only with sleep duration. 
13  
However, VLDL cholesterol levels 
were not reported in the CARDIA study, as we explored in this current study. In 
addition, there are several other mechanisms, besides sleep duration, that have been 
enrolled in the association between sleep disturbances and poor lipid profile. 
30, 31  
For 
instance, sleep fragmentation, classified as the number of microarousals during sleep, 
has been associated with increased levels of lipids, cortisol, and blood pressure. 
30 
A 
reasonable hypothesis to be considered is that poor sleep quality may be an 
epiphenomenon of other sleep-related metabolic changes, such as sleep fragmentation.
30 
Our results are consistent with these findings. Our findings demonstrated that other 
sleep disturbances besides OSA 
5-7, 13, 32-36 
and sleep duration, 
12, 13, 26, 27 
specifically 
sleep quality, may be potential risk factors for poor lipid profiles. A clear understanding 
of the biological mechanisms linking these sleep disturbances and higher VLDL 
cholesterol levels remains to be identified. 
 PSQI is a commonly used subjective sleep quality instrument.
18, 19, 37 
Despite the 
limitations due to its subjective nature, it has also been considered a tool that added 
significant contributions to the general quality of life (QoL) evaluation.
 37 
Our findings 
showed that the daytime dysfunction domain significantly associated with high levels of 
11 
 
both VLDL cholesterol and triglycerides, so it seems to be in line with previous report 
about the idea that the sleep may have significant impact on QoL, even in the absence of 
sleep disordered breathing or other health problems, such as lipid alterations. 
38
 
       Our study has some limitations. First, the cross-sectional nature does not allow 
causal inference. Second, although we adjust for major confounders, there may still be 
residual confounding due to incomplete adjustments and unknown confounders. Sleep 
medication use was analyzed separately, as it formed a component of PSQI 
questionnaire, and is shown in the supplemental data. We did not ascertain type of sleep 
medication or duration of use. Similarly, hypnotic medication was not taken into 
account separately in the current analysis. In addition, the subjective nature of the 
questionnaires should be carefully evaluated. Finally, overnight polygraphy was 
performed through a type III portable sleep study, which does not allow sleep duration 
to be objectively measured. Thus, sleep duration in the current study was self-reported. 
Moreover, portable overnight polygraphy may underdiagnose OSA, 
39, 40
 since there are 
no brain channels to assess respiratory events related to arousals. Therefore, our results 
should be interpreted with caution. 
 
5.0 CONCLUSION 
       Our findings revealed that poor sleep quality was independently associated with 
poorer lipid profile, specifically higher VLDL and triglycerides. Poor sleep quality may 
reflect an unhealthy lifestyle, but also may be an epiphenomenon of other sleep 
disturbances, beyond OSA and sleep duration. Our findings were robust even after 
adjusting for socio-economic status, but possible residual confounding caused by 
unknown factors should be considered in an observational study. An objectively 
12 
 
measured sleep evaluation, by a full polysomnography, may shed light the mechanistic 
pathways by which poor sleep quality may lead to elevated lipid blood levels.  
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Table 1. Univariate Analysis of All Complete Sleep Questionnaires (Full Sample) 
and Those Who Also Underwent Portable Sleep Study (Overnight Polygraphy; 
Analytical Sample)  
Demographics Full sample 
(n= 1,801 ) 
Analytical sample 
(n= 573) 
P-value 
Age, years 45 ±17            43 ±16             0.023 
Sex (male), % 42               34           <0.001 
Self-reported race, % 
 
White 
Black 
Mixed 
 
 
76 
6 
13 
 
 
80 
 4 
16 
0.005 
Smoking status, % 
 
Never 
Former 
Current 
 
 
66 
22 
12 
 
 
72 
20 
 8 
<0.001 
Alcohol use, % 
 
None 
<Once/month 
Once to 3 times/week 
Up to 3 times/month 
Daily 
Other 
 
 
70 
6 
10 
11 
1 
2 
 
 
73 
7 
9 
9 
1 
1 
0.260 
Salary, % 
 
Up to 1 minimum wage 
(MW) 
From 1 to 5 MW 
From 5 to 10 MW 
From 10 to 20 MW 
>20 MW 
No answer 
 
 
17 
 
76 
3.5 
1.0 
0.5 
2.0 
 
 
15 
 
78 
4.0 
0.5 
0.5 
2.0 
0.280 
Marital status, %   0.122 
19 
 
 
Married 
Single 
Divorced 
Widowed 
 
62 
26 
6 
6 
 
  62 
  27 
   5 
   6 
Education level,% 
 
Illiterate 
High school 
Technical training 
Graduation 
 
 
3 
82 
3 
12 
 
 
2 
81 
4 
13 
0.564 
BMI, kg/m
2
 26 ±5     26 ±5 0.740 
Waist circumference, cm 91 ±12 91 ±12 0.580 
Hip circumference, cm 98 ±10 98 ±10 0.670 
Neck circumference, cm 36 ±8 36 ±12 0.790 
Medication use, % 
 
Anti-hypertensive  
Hypoglicemic 
Lipid-lowering 
Oral contraceptive 
 
 
28 
5 
8 
15 
 
 
28 
6 
11 
18 
 
 
0.700 
0.210 
0.004 
0.965 
Post-menopausal status, 
% 
22 24 0.830 
Cardiometabolic risk 
factors 
  
 
VLDL-cholesterol, 
mg/dL 
25 ±12 25 ±11 0.190 
LDL-cholesterol, mg/dL 125 ±35 123 ±35 0.093 
HDL-cholesterol, mg/dL 47 ±12 48 ±11 0.490 
Total cholesterol, mg/dL 198 ±41 195 ±41 0.075 
Cholesterol ratio 4.40 ±1.30 4.30 ±1.30 0.052 
Triglycerides, mg/dL* 131 ±75 126 ±60 0.190 
Glucose, mg/dL 93 ±20 94 ±19 0.106 
HbA1c, % 5.7 ±0.8 5.7 ±0.7 0.084 
Systolic BP, mmHg 123 ±11 121 ±11 0.001 
Diastolic BP, mmHg 78 ±9 77 ±8 0.017 
Data are shown as mean ±SD for continuous and percentage for categorical variables. P-value is by 
independent t-test for continuous and normally distributed variables (the test is independent for each 
covariate) (P value indicates comparison of those included in analytic sample to those excluded) and by 
chi-square for categorical variables. BMI= body mass index; VLDL=very-low density lipoprotein; LDL= 
low-density lipoprotein; HDL= high-density lipoprotein; cholesterol ratio= total cholesterol/HDL; 
HbA1c= glycated hemoglobin; BP= blood pressure. 
*Since triglycerides was skewed, the P-value is by Mann-Whitney, a non-parametric test. The median and 
IQR (25
th
, 75
th
) for triglycerides in the Full sample is 116 (85, 158) mg/dL and in the Analytical sample is 
112 (87, 154) mg/dL. 
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Table 2. Univariate Analysis of All Complete Sleep Questionnaires (Full Sample) 
and Those Who Also Underwent Portable Sleep Study (Overnight Polygraphy; 
Analytical Sample)  
Sleep characteristics 
Full sample 
(n= 1,801) 
     Analytical 
       Sample 
       (n= 573) 
P-value 
AHI, events/h - 10 ±10              - 
ODI, events/h - 10 ±11              - 
Nadir SpO2, -           82 ±10 - 
Basal SpO2 -           95 ±5 - 
AHI ≥ 5, % - 58 - 
AHI ≥ 15, % - 18 - 
AHI ≥ 30, % - 5 - 
ESS continuous score 7 ±5            7±5 0.094 
ESS >10, % 30 34 0.009 
PSQI total score 5 ±3 5±3 0.095 
PSQI ≥ 5, % 46 50 0.018 
Sleep duration  
(self-reported) ≥ 6h,% 
94 93 0.180 
Sleep duration  
(self-reported),  min 
472 ±106 461 ±87 0.002 
Sleep efficiency, % 92 ±34 93 ±16 0.200 
Bed time  
(hours: minutes)* 
22:44 ±01:60 22:40 ± 01:40 <0.001 
Data are shown as mean ±SD for continuous and percentage for categorical variables. P-value is by 
independent t-test for continuous and normally distributed variables (the test is independent for each 
covariate) (P value indicates comparison of those included in analytic sample to those excluded) and by 
chi-square for categorical variables. OSA= obstructive sleep apnea; BMI= body mass index; AHI= apnea-
hypopnea index; ODI= oxygen desaturation index (with 4% drop in oxygen saturation); SpO2= oxygen 
saturation; AHI ≥5= mild OSA; AHI ≥15= moderate OSA; AHI ≥30= severe OSA; ESS= Epworth 
sleepiness scale; ESS >10= excessive daytime sleepiness; PSQI= Pittsburgh sleep quality index; PSQI 
≥5= poor sleep quality;  
*Bedtime = median and IQR 25
th
, 75
th
 (22:50 and 21:50, 23:50) for the full sample. Bedtime = median 
and IQR 25
th
, 75
th
 (22:50 and 21:50, 23:50) for the analytical sample. Bedtime was skewed, so P-value by 
Mann-Whitney, a non-parametric test. 
Those left blank were not measured by polygraphy. 
 
 
 
 
21 
 
Table 3. Multivariable Linear Regression Analysis Testing Association of CV Risk 
Factors (Outcome) and PSQI (main Predictor) 
 
PSQI total score PSQI <5 vs ≥ 5 
Outcome variable Beta Se P-value Beta se P-value 
VLDL-cholesterol, mg/dL 0.392 0.156 0.012 1.763 0.980 0.072 
ln Triglycerides, mg/dL 0.017 0.006 0.006 0.071 0.040 0.071 
HDL-cholesterol, mg/dL -0.194 0.155 0.208 -0.897 0.973 0.356 
LDL-cholesterol, mg/dL 0.082 0.500 0.870 1.886 3.120 0.546 
Total cholesterol, mg/dL 0.495 0.561 0.377 2.932 3.532 0.407 
Cholesterol ratio 0.033 0.017 0.060 0.195 0.110 0.077 
Glucose, mg/dL 0.180 0.247 0.468 -0.601 1.560 0.700 
HbA1c, % -0.015 0.009 0.102 -0.066 0.056 0.238 
Systolic BP, mmHg* 0.073 0.152 0.634 0.516 0.961 0.613 
Diastolic BP, mmHg* 0.060 0.116 0.602 0.290 0.731 0.693 
CV= cardiovascular; VLDL= very-low density lipoprotein; ln= natural logarithm transformation; HDL= 
high-density lipoprotein; LDL= low-density lipoprotein; cholesterol ratio= total cholesterol/HDL; 
HbA1c= glycated hemoglobin; BP= blood pressure; PSQI= Pittsburgh sleep quality index; PSQI ≥5= 
poor sleep quality; BMI= body mass index; ESS= Epworth sleepiness scale; OSA= obstructive sleep 
apnea; AHI= apnea hypopnea index (number of events per hour of sleep); se= standard error. Each line 
represents a unique regression model. Adjustments for age, sex (female= ref), race (White vs others), 
Wage categories (up to 5 MW vs >5MW and >5MW as ref), Education categories (illiterate vs high 
school vs technical/graduation and illiterate as ref), smoking status (never as ref), systolic BP, BMI, sleep 
duration (minutes); ESS continuous score, bedtime (in hours), and OSA by AHI continuous score. 
Missing data were excluded (all complete for regression analysis= 554). 
*not included systolic BP in adjustments. 
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Table 4. Restricted Analysis for those Without OSA (AHI<15), Testing the 
Association Between Lipid Components (Outcome) and Sleep Quality (n= 472) 
 
VLDL-cholesterol, mg/dL ln Triglycerides, mg/dL 
 Beta se P-value Beta se P-value 
PSQI 
total 
score 
0.446 0.170 0.009 0.018 0.007 0.010 
PSQI 
cutoff 5 
2.188 1.037 0.035 0.084 0.426 0.048 
OSA= obstructive sleep apnea; AHI= apnea hypopnea index; VLDL= very-low density lipoprotein 
cholesterol; ln= natural logarithm transformation; se= standard error; PSQI= Pittsburgh sleep quality 
index; PSQI ≥5= poor sleep quality; BMI= body mass index; ESS= Epworth sleepiness scale; BP= blood 
pressure. Adjustments: age, sex (female= ref), race (White vs others), Wage categories (up to 5 MW vs 
>5MW and >5MW as ref), Education categories (illiterate vs high school vs technical/graduation and 
illiterate as ref), smoking status (never as reference), BMI, ESS continuous score, sleep duration 
(minutes), bedtime (in hours), and daytime systolic BP. Missing data were excluded. All complete for 
regression analysis (n=423). 
 
 
 
Table 5. Restricted Analysis for those Without Lipid-lowering Medication (n= 510) 
Testing the Association Between Lipid Components (Outcome) and Sleep Quality  
 
VLDL-cholesterol, mg/dL ln Triglycerides, mg/dL 
 Beta se P-value Beta se P-value 
PSQI 
total 
score 
0.426 0.161 0.008 0.019 0.006 0.004 
PSQI 
cutoff 5 
1.681 1.013 0.097 0.080 0.040 0.047 
VLDL= very-low density lipoprotein cholesterol; ln= natural logarithm transformation; se= standard 
error; PSQI= Pittsburgh sleep quality index; PSQI ≥5= poor sleep quality; BMI= body mass index; ESS= 
Epworth sleepiness scale; BP= blood pressure, AHI= apnea hypopnea index. Adjustments: age, sex 
(female=ref), race (White vs others), Wage categories (up to 5 MW vs >5MW and >5MW as ref), 
Education categories (illiterate vs high school vs technical/graduation and illiterate as ref), smoking status 
(never as reference), BMI, ESS continuous score, sleep duration (minutes), bedtime (in hours), AHI, and 
daytime systolic BP. Missing data were excluded. All complete for regression analysis (n= 462). 
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ABSTRACT 
 
Aim: To test the association between cardiometabolic risk factors and subjective sleep 
quality assessed by the Pittsburgh sleep quality index (PSQI), independent of 
obstructive sleep apnea (OSA) and sleep duration. 
Methods: 573 participants from the Baependi Heart Study, a rural cohort from Brazil 
that completed sleep questionnaires and underwent polygraphy for OSA evaluation. 
Multivariable linear regression analysis tested the association between cardiovascular 
risk factors (outcome variables) and sleep quality measured by PSQI, adjusting for OSA 
and other potential confounders (age, sex, race, salary/wage, education, marital status, 
alcohol intake, obesity, smoking, hypertension, and sleep duration).  
Results: The sample mean age was of 43±16y, 66% were female, and mean body mass 
index (BMI) was 26±5 kg/m
2
. Only 20% were classified as obese (BMI ≥30). Fifty 
percent of participants reported poor sleep quality as defined by a PSQI score ≥5. A 
high PSQI score was significantly associated with higher very-low density lipoprotein 
(VLDL) cholesterol levels (beta=0.392, p=0.012) and higher triglyceride levels 
(beta=0.017, p=0.006), even after adjustments, including the apnea-hypopnea index. 
Further adjustments accounting for marital status, alcohol intake, and medication use 
did not change these findings. No significant association was observed between PSQI 
scores and glucose or blood pressure. According to PSQI components, sleep 
disturbances (beta=1.976, p=0.027), sleep medication use (beta=1.121, p=0.019), and 
daytime dysfunction (beta=1.290, p=0.024) were significantly associated with higher 
VLDL serum levels. Only the daytime dysfunction domain of the PSQI components 
was significantly associated with higher triglyceride levels (beta=0.066, p=0.004).  
Conclusion: Poorer lipid profile was independently associated with poor sleep quality, 
assessed by the PSQI questionnaire, regardless of a normal sleep duration and 
accounting for OSA and socio-economic status.  
 
Keywords: lipids; sleep quality; PSQI; Pittsburgh Sleep Quality Index; very-low 
density lipoprotein cholesterol; low-density lipoprotein cholesterol; obstructive sleep 
apnea  
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1.0 INTRODUCTION 
        Sleep disturbances have been associated with metabolic dysregulation and may 
contribute to weight gain, obesity, and diabetes. 
1-6
 Obstructive sleep apnea (OSA) is 
known to explain part of this association, but other factors besides OSA are thought to 
also play a role.
7-13
 For example, poor sleep quality has been associated with obesity, 
diabetes and weight gain, 
8, 9, 11, 12 
but few studies have shown these associations in the 
absence of OSA. 
8, 11 
In addition, there is still controversy about the association between 
poor sleep quality and the lipid profile, once a poorer lipid profile has been initially 
associated only with sleep duration, but not with self-reported sleep quality. 
13 
However, 
a worse lipid profile was also independently associated with poor subjective sleep 
quality scores. 
12
 
       The aim of the current study is to test whether there is an independent association 
between subjective sleep quality, assessed by the Pittsburgh sleep quality index (PSQI) 
questionnaire, and cardiometabolic factors, while adjusting for OSA in a sample from 
the general population. 
 
2.0 METHODS 
2.1 Study cohort 
The Baependi Heart Study, now in its 12
th
 year, is a family-based cohort study aimed at 
evaluating genetic and environmental influences on cardiovascular risk factors. 
14, 15 
Baependi is
 
a small rural town in the state of Minas Gerais, Brazil, with very limited 
inward migration.  At baseline, 1691 individuals across 95 families were evaluated. 
Cross-sectional data have been collected for 2,239 participants. 
15
 The current study 
analyzed a subset of participants at the second evaluation period (from 2010 to 2014). 
4 
 
All participants in this subset had completed sleep questionnaires (the PSQI and 
Epworth sleepiness scale-ESS) (n=1,801), and underwent OSA evaluation by overnight 
polygraphy (n= 573). We only studied individuals with complete sleep questionnaire 
data and sleep polygraphy. Our sample size is contingent on the fact that the sleep 
polygraphy protocol was only performed in a subset of participants. There was no 
specific inclusion criteria for the polygraphy protocol and all individuals from the total 
sample were invited to participate in the sleep polygraphy protocol. 
The study protocol was approved by the ethics committee of the Hospital das Clinicas, 
University of São Paulo, Brazil, and each subject provided informed written consent 
before participation. 
 
2.2 Covariates 
Anthropometric measures, such as height, weight, waist, hip, and neck circumferences, 
were measured following standardized procedures as previously described.
16
 Body mass 
index (BMI) was calculated from height and weight (kg/m
2
).  Smoking status was 
defined by asking the question: “Have you smoked cigarettes...?” Being possible 
answers: (1) Yes, in the past, but not currently; (2) Yes, and I still smoke; (3) I have 
never smoked. The three choices were thus characterized as (1) former, (2) current, and 
(3) non-smokers, respectively. 
17 
Seated systolic blood pressure (SBP) and diastolic 
blood pressure (DBP) were assessed by one trained examiner. The mean out of three 
measures was used to describe blood pressure at rest. Medication use, alcohol use, 
salary, education level, and marital status were assessed by questionnaires. 
 
2.3 Sleep questionnaires 
5 
 
The PSQI is a self-rated questionnaire which assesses sleep quality over the past month. 
Nineteen individual items generate seven component scores: subjective sleep quality, 
habitual sleep efficiency, sleep latency, sleep duration, sleep disturbances, use of 
sleeping medication, and daytime dysfunction. A global PSQI score equal or greater 
than five has been proposed to distinguish between good and poor sleepers. 
18, 19
 
The ESS is a self-administered questionnaire that provides a measurement of daytime 
sleepiness. The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. 
Excessive daytime sleepiness is defined as a score >10. 
20
 
 
2.4 Other sleep measures 
The diagnosis of OSA was made based on a portable type III study (Stardust II; Philips, 
Eindhoven, Netherlands). The overnight sleep monitor was installed by a technician at 
the patient’s home. Briefly, the portable monitor used pulse oximetry, airflow detection 
through nasal cannula pressure, position sensor, heart rate recorded by pulse oximetry, 
and respiratory effort (chest-strap piezoelectric detection). Apneas were classified as 
central (absence of airflow or ≥90% reduction of baseline for ≥10s associated with the 
absence of thoracic and abdominal effort), obstructive (absence of airflow or ≥90% 
reduction of baseline for ≥10s associated with the presence of thoracic and abdominal 
effort), or mixed (absence of airflow or ≥90% reduction of baseline for ≥10s in the 
presence of thoracic and abdominal effort at the end of the event). 
21, 22 
Hypopneas were 
classified as a 30% or more drop in airflow for ≥10s with a 4% decrease in oxygen 
desaturation. 
21, 22 
The apnea hypopnea index (AHI) was assessed by the number of 
respiratory events (apneas and hypopneas) divided by the total sleep recording time. 
The OSA severity was determined according to standard cutoffs as mild (AHI 5-14), 
6 
 
moderate (AHI 15-29) or severe (AHI ≥30). 21,  22  More details about the polygraphy 
exam were previously described. 
23
 
Bedtime and sleep duration were self-reported on the PSQI. Sleep efficiency 
information was extracted from the PSQI questionnaire. Data from sleep duration of this 
cohort has been previously published.
14
 
 
2.5 Metabolic risk factors 
Fasting blood glucose, glycated hemoglobin (HbA1c), total cholesterol, lipoprotein 
fractions, and triglycerides were assayed by standard techniques in 12-hour fasting 
blood samples. Serum samples were stored at -80°C prior to analysis. We also tested the 
cholesterol ratio (total cholesterol divided by high-density lipoprotein (HDL) 
cholesterol). 
24, 25
 
 
2.6 Statistical Analysis 
Descriptive analyses are shown as mean ±SD for continuous and percentage for 
categorical variables. Natural log transformation (ln) was used in cases of departure 
from normality. Because triglycerides showed high kurtosis we log transformed this 
variable (ln) while running linear regression analysis. Multivariable linear regression 
analysis was used to test the independent relationship between cardiovascular risk 
factors as outcome variables (lipid/glucose blood levels and blood pressure) and sleep 
quality as a main predictor (assessed by the PSQI), adjusting for age, sex, race, salary 
(monthly), education level, smoking status (never, former, current), BMI, SBP, daytime 
sleepiness (by ESS-continuous score), AHI continuous score, sleep duration, and 
bedtime. Further adjustments were also made for lipid-lowering medication use, blood 
glucose levels, alcohol use, and marital status. We have also run sensitivity analysis 
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excluding those with OSA (AHI ≥15) in order to explore the association between 
cardiometabolic factors and sleep quality independent of OSA. Similarly, we performed 
a restricted analysis for participants who did not use lipid-lowering medication. Sleep 
quality by the PSQI was used as a continuous score, a dichotomous category (cutoff 5), 
and by its seven domains. The final sample size for the current analysis was 573 
participants, who underwent overnight polygraphy and had completed sleep 
questionnaires. We show descriptive data from the full sample (n=1,801) and from 
those used in the present analysis (n=573). We tested whether those included in our 
analytic sample differed significantly from those who did not participate in the 
polygraphy examinations using independent t tests for continuous variables or chi 
squared tests for categorical variables. Missing data were excluded while running 
regression analysis. Data were analyzed by the IBM SPSS statistics software version 18. 
The alpha level of significance was set as <0.05. 
 
3.0 RESULTS 
        Table 1 shows descriptive data from the total and the analytical sample for 
demographics and cardiovascular risk factors. The analytical sample is predominantly 
female (66%), mean age was 43±16y, age range from 18 to 81yo, and mean BMI of 
26±5kg/m
2
. Overweight (BMI between 25 and 30) participants were 30% and only 20% 
were classified as obese subjects (BMI ≥30). Most reported never having smoked and 
not using alcohol. Almost one quarter of the women in the sample was post-menopausal 
and almost 30% of the sample used anti-hypertensive medication. In general, 
cardiovascular risk factors were within normal ranges. The analytical sample showed a 
similar distribution of variables (demographic and cardiometabolic factors) compared to 
the full sample, except for age, sex, race, smoking status, and blood pressure levels. 
8 
 
Table 2 shows sleep characteristics according to questionnaires and polygraphy. Fifty 
percent classified their sleep quality as poor by the PSQI, and 34% reported excessive 
daytime sleepiness. OSA, by polygraphy, was shown in 18% of the study sample. Sleep 
efficiency was considered to be normal (>85%) and self-reported sleep duration 
indicated that the majority of them slept more than 6h/night. Self-reported bedtime 
showed a mean bedtime of 22:40. The analytical sample showed a slightly higher 
percentage of participants with poor sleep quality by the PSQI compared to full sample 
participants (50 vs 46%, respectively). Likewise, the analytical sample showed higher 
percentage of participants with excessive daytime sleepiness compared to participants 
from full sample (34 vs 30%, respectively). After testing for independent associations 
between sleep quality and cardiovascular risk factors, only VLDL cholesterol and 
triglyceride levels remained significantly associated with higher PSQI scores (Table 3). 
To explore other potential confounding factors relating poor sleep quality with the lipid 
profile, we further adjusted for lipid-lowering medication use, fasting glucose levels, 
alcohol use, and marital status. Results remained similar (supplemental material-
appendix A1). To test the association between sleep quality and cardiometabolic risk 
variables, independently of OSA, we also performed an analysis only for those with an 
AHI<15, that is, excluding those with moderate-to-severe OSA. The results remained 
statistically significant (Table 4). In addition, we have also run a restricted analysis 
excluding those taking lipid-lowering medication. The findings remained significant 
(Table 5).  
       Furthermore, we evaluated the PSQI by components as main predictors. 
Supplemental material shows all multiple regression analyses testing PSQI components 
association with cardiovascular risk factors. According to PSQI components, we have 
first modeled them as continuous scores, and then, if statistically significant, they were 
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modeled within strata. Higher scores in the daytime dysfunction domain (showed 
overall and within strata) were significantly associated with higher ln (triglycerides) 
levels (p=0.004) (Appendix A2). The sleep disturbances domain (p=0.027), sleep 
medication use domain (p=0.019), and daytime dysfunction domain (p=0.024) were 
significantly associated with higher VLDL blood levels (Appendix A3).  
 
4.0 DISCUSSION 
         Prior evidence supports that sleep duration and quality may be a potentially 
modifiable risk factor for cardiovascular and metabolic disease. We tested for 
associations between cardiometabolic variables and poor sleep quality, assessed by the 
PSQI, controlling for sleep duration and severity of OSA. Our findings showed that (1) 
50% of this rural-based population reported poor sleep quality, even within a normal 
sleep duration range; (2) higher VLDL cholesterol and triglycerides levels were 
associated with higher PSQI score (i.e. worse sleep quality), even after adjusting for 
potential confounders; and (3) the PSQI component most significantly associated with 
both high VLDL and triglyceride blood levels was daytime dysfunction. Importantly, 
our results appear to be independent of OSA as we have not only adjusted for AHI 
(continuous score), but also tested for these associations excluding those with moderate-
to-severe OSA (AHI ≥15) and the results remained statistically significant. Our results 
are in line with the hypothesis that lipid alterations may be early markers of metabolic 
dysfunction induced by poor sleep quality. 
        There are complex mechanisms behind the association between sleep duration and 
cardiovascular risk factors, since both short 
3, 10, 26, 27 
and long sleep duration
 12, 13
 have 
been associated with cardiometabolic alterations. Studies have shown that obesity is 
associated with poor sleep quality, sleep fragmentation, and sleep duration.
3, 4, 7
 
10 
 
However, only few of these studies tested this association in the absence of OSA.
 8, 9, 11 
A higher PSQI score has been associated with larger waist circumferences, BMI, and 
percentage of body fat, as well as with higher serum levels of insulin and glucose. 
28 
Nonetheless, associations between PSQI and lipids (HDL cholesterol and triglycerides) 
have been inconsistent, being reported to be negative, 
28
 and positive. 
29 
In the scenario of the controversy about the association between lipid profile and 
sleep quality, 
28, 29
 the CARDIA study showed that a higher PSQI score was not 
significantly associated with a poorer lipid profile. 
13
 The poorer lipid profile was 
statistically associated only with sleep duration. 
13  
However, VLDL cholesterol levels 
were not reported in the CARDIA study, as we explored in this current study. In 
addition, there are several other mechanisms, besides sleep duration, that have been 
enrolled in the association between sleep disturbances and poor lipid profile. 
30, 31  
For 
instance, sleep fragmentation, classified as the number of microarousals during sleep, 
has been associated with increased levels of lipids, cortisol, and blood pressure. 
30 
A 
reasonable hypothesis to be considered is that poor sleep quality may be an 
epiphenomenon of other sleep-related metabolic changes, such as sleep fragmentation.
30 
Our results are consistent with these findings. Our findings demonstrated that other 
sleep disturbances besides OSA 
5-7, 13, 32-36 
and sleep duration, 
12, 13, 26, 27 
specifically 
sleep quality, may be potential risk factors for poor lipid profiles. A clear understanding 
of the biological mechanisms linking these sleep disturbances and higher VLDL 
cholesterol levels remains to be identified. 
 PSQI is a commonly used subjective sleep quality instrument.
18, 19, 37 
Despite the 
limitations due to its subjective nature, it has also been considered a tool that added 
significant contributions to the general quality of life (QoL) evaluation.
 37 
Our findings 
showed that the daytime dysfunction domain significantly associated with high levels of 
11 
 
both VLDL cholesterol and triglycerides, so it seems to be in line with previous report 
about the idea that the sleep may have significant impact on QoL, even in the absence of 
sleep disordered breathing or other health problems, such as lipid alterations. 
38
 
       Our study has some limitations. First, the cross-sectional nature does not allow 
causal inference. Second, although we adjust for major confounders, there may still be 
residual confounding due to incomplete adjustments and unknown confounders. Sleep 
medication use was analyzed separately, as it formed a component of PSQI 
questionnaire, and is shown in the supplemental data. We did not ascertain type of sleep 
medication or duration of use. Similarly, hypnotic medication was not taken into 
account separately in the current analysis. In addition, the subjective nature of the 
questionnaires should be carefully evaluated. Finally, overnight polygraphy was 
performed through a type III portable sleep study, which does not allow sleep duration 
to be objectively measured. Thus, sleep duration in the current study was self-reported. 
Moreover, portable overnight polygraphy may underdiagnose OSA, 
39, 40
 since there are 
no brain channels to assess respiratory events related to arousals. Therefore, our results 
should be interpreted with caution. 
 
5.0 CONCLUSION 
       Our findings revealed that poor sleep quality was independently associated with 
poorer lipid profile, specifically higher VLDL and triglycerides. Poor sleep quality may 
reflect an unhealthy lifestyle, but also may be an epiphenomenon of other sleep 
disturbances, beyond OSA and sleep duration. Our findings were robust even after 
adjusting for socio-economic status, but possible residual confounding caused by 
unknown factors should be considered in an observational study. An objectively 
12 
 
measured sleep evaluation, by a full polysomnography, may shed light the mechanistic 
pathways by which poor sleep quality may lead to elevated lipid blood levels.  
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AHI= apnea hypopnea index 
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PSQI= Pittsburgh sleep quality index 
SBP= systolic blood pressure 
VLDL= very-low-density lipoprotein 
 
7.0 REFERENCES 
1. Depner CM, Stothard ER, Wright KP Jr.Metabolic consequences of sleep and 
circadian disorders.CurrDiab Rep. 2014 Jul;14(7):507. 
2. Nedeltcheva AV, Scheer FA. Metabolic effects of sleep disruption, links to obesity 
and diabetes.CurrOpinEndocrinol Diabetes Obes. 2014 Aug;21(4):293-8. 
3. Lauderdale DS, Knutson KL, Rathouz PJ, et al. Cross-sectional and longitudinal 
associations between objectively measured sleep duration and body mass index: the 
CARDIA Sleep Study. Am J Epidemiol.2009; 170:805–813.  
4. Beccuti G, Pannain S. Sleep and obesity. CurrOpinClinNutrMetab Care. 2011 
Jul;14(4):402-12.  
5. Dempsey JA, Veasey SC, Morgan BJ, O'Donnell CP. Pathophysiology of sleep 
apnea. Physiol Rev. 2010 Jan;90(1):47-112. 
6. Caples SM, Gami AS, Somers VK. Obstructive sleep apnea.Ann Intern Med. 2005; 
142:187–197. 
7. Phillips BG, Kato M, Narkiewicz K, Choe I, Somers VK. Increases in leptin levels, 
sympathetic drive, and weight gain in obstructive sleep apnea. Am J Physiol Heart Circ 
Physiol. 2000; 279:H234–237. 
14 
 
8. Resta O, FoschinoBarbaro MP, Bonfitto P, et al. Low sleep quality and daytime 
sleepiness in obese patients without obstructive sleep apnoea syndrome. J Intern Med. 
2003; 253:536–543.  
9. Lyytikainen P, Lallukka T, Lahelma E, Rahkonen O. Sleep problems and major 
weight gain: a follow-up study. Int J Obes (Lond).2011; 35:109–114.  
10. Knutson KL. Sleep duration and cardiometabolic risk: a review of the epidemiologic 
evidence. Best Pract Res ClinEndocrinolMetab. 2010 Oct;24(5):731-43. 
11. Bidulescu A, Din-Dzietham R, Coverson DL, et al. Interaction of sleep quality and 
psychosocial stress on obesity in African Americans: the Cardiovascular Health 
Epidemiology Study (CHES). BMC Public Health.2010; 10:581.  
12. Hung HC, Yang YC, Ou HY, Wu JS, Lu FH, Chang CJ. The association between 
self-reported sleep quality and metabolic syndrome. PLoS One. 2013;8(1):e54304. 
13. Petrov ME, Kim Y, Lauderdale D, Lewis CE, Reis JP, Carnethon MR, Knutson K, 
Glasser SJ. Longitudinal associations between objective sleep and lipids: the CARDIA 
study. Sleep. 2013 Nov 1;36(11):1587-95. 
14. Beijamini F, Knutson KL, Lorenzi-Filho G, Egan KJ, Taporoski TP, De Paula LK, 
Negrão AB, Horimoto AR, Duarte NE, Vallada H, Krieger JE, Pedrazzoli M, Pereira 
AC, von Schantz M. Timing and quality of sleep in a rural Brazilian family-based 
cohort, the Baependi Heart Study. Sci Rep. 2016 Dec23;6:39283. 
15. Egan KJ, vonSchantz M1, Negrão AB, Santos HC, Horimoto AR, Duarte NE, 
Gonçalves GC, Soler JM, de Andrade M, Lorenzi-Filho G, Vallada H, Taporoski TP, 
Pedrazzoli M, Azambuja AP, de Oliveira CM, Alvim RO, Krieger JE, Pereira AC. 
Cohort profile: the Baependi Heart Study-a family-based, highly admixed cohort study 
in a rural Brazilian town. BMJ Open. 2016 Oct21;6(10):e011598. 
15 
 
16. de Oliveira CM, Ulbrich AZ, Neves FS, Dias FAL, Horimoto ARVR, Krieger JE, 
Alvim RO, Pereira AC. Association between anthropometric indicators of adiposity and 
hypertension in a Brazilian population: Baependi Heart Study. PLoSOne. 2017 
Oct12;12(10):e0185225. 
17. Horimoto AR, Oliveira CM, Giolo SR, Soler JP, de Andrade M, Krieger JE, Pereira 
AC.Genetic analyses of smoking initiation, persistence, quantity, and age-at-onset of 
regular cigarette use in Brazilian families: the Baependi Heart Study. BMC Med Genet. 
2012 Jan 30;13:9. 
18. Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh 
Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatr 
Res 1989;28:193-213. 
19. Bertolazi AN, Fagondes SC, Hoff LS, Dartora EG, Miozzo IC, de Barba ME, 
Barreto SS. Validation of the Brazilian Portuguese version of the Pittsburgh Sleep 
Quality Index. Sleep Med. 2011 Jan;12(1):70-5. 
20. Johns, M. W. A new method for measuring daytime sleepiness: the Epworth 
sleepiness scale. Sleep 1991;14:540–545. 
21. Sleep-related breathing disorders inadults: recommendations for syndromedefinition 
and measurement techniquesin clinical research. The report ofan American Academy of 
Sleep MedicineTaskForce.Sleep. 1999;22(5):667-689. 
22. Iber C, Ancoli-Israel S, ChessonA,Quan S. The AASM Manual for theScoring of 
Sleep and Associated Events,Rules, Terminology and technicalSpecifications. AASM 
Manual forScoring Sleep. Westchester, IL:American Academy of Sleep 
Medicine;2007:59. 
16 
 
23. de Paula LK, Alvim RO, Pedrosa RP, Horimoto AR, Krieger JE, Oliveira CM, 
Pereira AC, Lorenzi-Filho G. Heritabilityof OSA in a Rural Population. Chest.2016 
Jan;149(1):92-7. 
24. Executive Summary of The Third Report of The National Cholesterol Education 
Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood 
Cholesterol In Adults (Adult Treatment Panel III). JAMA.2001; 285:2486–2497.  
25. Lemieux I, Lamarche B, Couillard C, Pascot A, Cantin B, Bergeron J, Dagenais GR, 
Després JP. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL 
cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec 
Cardiovascular Study. Arch Intern Med. 2001 Dec 10-24;161(22):2685-92. 
26.van den Berg JF, KnvistinghNeven A, Tulen JH, et al. Actigraphic sleep duration 
and fragmentation are related to obesity in the elderly: the Rotterdam Study. Int J Obes 
(Lond).2008; 32:1083–1090.  
27. Beihl DA, Liese AD, Haffner SM. Sleep duration as a risk factor for incident type 2 
diabetes in a multiethnic cohort. Ann Epidemiol. 2009 May;19(5):351-7. 
28. Jennings JR, Muldoon MF, Hall M, Buysse DJ, Manuck SB. Self-reported sleep 
quality is associated with the metabolic syndrome. Sleep. 2007 Feb;30(2):219-23. 
29. Hung HC, Yang YC, Ou HY, Wu JS, Lu FH, Chang CJ.The association between 
self-reported sleep quality and metabolic syndrome.PLoS One. 2013;8(1):e54304.  
30. Ekstedt M, Åkerstedt T, Söderström S. Microarousals during sleep are associated 
with increased levels of lipids, cortisol, and blood pressure. Psychosom Med 
2004;66:925-31. 
31. Van Den Berg JF, Miedema HM, Tulen JH, et al. Long sleep duration is associated 
with serum cholesterol in the elderly: the Rotterdam Study. Psychosom Med 
2008;70:1005-11. 
17 
 
32. Iesato K, Tatsumi K, Saibara T, Nakamura A, Terada J, Tada Y, Sakao S, Tanabe N, 
Takiguchi Y, Kuriyama T. Decreased lipoprotein lipase in obstructive sleep apnea 
syndrome. Circ J. 2007 Aug;71(8):1293-8. 
33. Drager LF, Li J, Shin MK, Reinke C, Aggarwal NR, Jun JC, Bevans-Fonti S, 
Sztalryd C, O'Byrne SM, Kroupa O, Olivecrona G, Blaner WS, Polotsky VY. 
Intermittent hypoxia inhibits clearance of triglyceride-rich lipoproteins and inactivates 
adipose lipoprotein lipase in a mouse model of sleep apnoea. Eur Heart J. 2012 
Mar;33(6):783-90. 
34. Jun JC, Shin MK, Yao Q, Bevans-Fonti S, Poole J, Drager LF, Polotsky VY. Acute 
hypoxia induces hypertriglyceridemia by decreasing plasma triglyceride clearance in 
mice. Am J PhysiolEndocrinolMetab. 2012 Aug 1;303(3):E377-88. 
35. Delezie J, Dumont S, Dardente H, Oudart H, Gréchez-Cassiau A, Klosen P, Teboul 
M, Delaunay F, Pévet P, Challet E. The nuclear receptor REV-ERBα is required for the 
daily balance of carbohydrate and lipid metabolism. FASEB J. 2012 Aug;26(8):3321-
35. 
36. Raspé E, Duez H, Mansén A, Fontaine C, Fiévet C, Fruchart JC, Vennström B, 
Staels B. Identification of Rev-erbalpha as a physiological repressor of apoC-III gene 
transcription. J Lipid Res. 2002 Dec;43(12):2172-9. 
37. Marques DR, Meia-Via AMS, da Silva CF, Gomes AA. Associations between sleep 
quality and domains of quality of life in a non-clinical sample: results from higher 
education students. Sleep Health. 2017 Oct;3(5):348-356. 
38. Buysse DJ. Sleep health: can we define it? Does it matter? Sleep. 2014 Jan 
1;37(1):9-17. 
39. Masa JF, Corral J, Pereira R, Duran-Cantolla J, Cabello M, Hernández-Blasco L, 
Monasterio C, Alonso A, Chiner E, Zamorano J, Aizpuru F, Montserrat JM; Spanish 
18 
 
Sleep Network. Therapeutic decision-making for sleep apnea and hypopnea syndrome 
using home respiratory polygraphy: a large multicentric study. Am J Respir Crit Care 
Med. 2011 Oct 15;184(8):964-71. 
40. Collop NA, Anderson WM, Boehlecke B, et al. ; Portable Monitoring Task Force of 
the American Academy of Sleep Medicine Clinical guidelines for the use of unattended 
portable monitors in the diagnosis of obstructive sleep apnea in adult patients. J Clin 
Sleep Med. 2007;3(7):737-747. 
 
 
 
 
Table 1. Univariate Analysis of All Complete Sleep Questionnaires (Full Sample) 
and Those Who Also Underwent Portable Sleep Study (Overnight Polygraphy; 
Analytical Sample)  
Demographics Full sample 
(n= 1,801 ) 
Analytical sample 
(n= 573) 
P-value 
Age, years 45 ±17            43 ±16             0.023 
Sex (male), % 42               34           <0.001 
Self-reported race, % 
 
White 
Black 
Mixed 
 
 
76 
6 
13 
 
 
80 
 4 
16 
0.005 
Smoking status, % 
 
Never 
Former 
Current 
 
 
66 
22 
12 
 
 
72 
20 
 8 
<0.001 
Alcohol use, % 
 
None 
<Once/month 
Once to 3 times/week 
Up to 3 times/month 
Daily 
Other 
 
 
70 
6 
10 
11 
1 
2 
 
 
73 
7 
9 
9 
1 
1 
0.260 
Salary, % 
 
Up to 1 minimum wage 
(MW) 
From 1 to 5 MW 
From 5 to 10 MW 
From 10 to 20 MW 
>20 MW 
No answer 
 
 
17 
 
76 
3.5 
1.0 
0.5 
2.0 
 
 
15 
 
78 
4.0 
0.5 
0.5 
2.0 
0.280 
Marital status, %   0.122 
19 
 
 
Married 
Single 
Divorced 
Widowed 
 
62 
26 
6 
6 
 
  62 
  27 
   5 
   6 
Education level,% 
 
Illiterate 
High school 
Technical training 
Graduation 
 
 
3 
82 
3 
12 
 
 
2 
81 
4 
13 
0.564 
BMI, kg/m
2
 26 ±5     26 ±5 0.740 
Waist circumference, cm 91 ±12 91 ±12 0.580 
Hip circumference, cm 98 ±10 98 ±10 0.670 
Neck circumference, cm 36 ±8 36 ±12 0.790 
Medication use, % 
 
Anti-hypertensive  
Hypoglicemic 
Lipid-lowering 
Oral contraceptive 
 
 
28 
5 
8 
15 
 
 
28 
6 
11 
18 
 
 
0.700 
0.210 
0.004 
0.965 
Post-menopausal status, 
% 
22 24 0.830 
Cardiometabolic risk 
factors 
  
 
VLDL-cholesterol, 
mg/dL 
25 ±12 25 ±11 0.190 
LDL-cholesterol, mg/dL 125 ±35 123 ±35 0.093 
HDL-cholesterol, mg/dL 47 ±12 48 ±11 0.490 
Total cholesterol, mg/dL 198 ±41 195 ±41 0.075 
Cholesterol ratio 4.40 ±1.30 4.30 ±1.30 0.052 
Triglycerides, mg/dL* 131 ±75 126 ±60 0.190 
Glucose, mg/dL 93 ±20 94 ±19 0.106 
HbA1c, % 5.7 ±0.8 5.7 ±0.7 0.084 
Systolic BP, mmHg 123 ±11 121 ±11 0.001 
Diastolic BP, mmHg 78 ±9 77 ±8 0.017 
Data are shown as mean ±SD for continuous and percentage for categorical variables. P-value is by 
independent t-test for continuous and normally distributed variables (the test is independent for each 
covariate) (P value indicates comparison of those included in analytic sample to those excluded) and by 
chi-square for categorical variables. BMI= body mass index; VLDL=very-low density lipoprotein; LDL= 
low-density lipoprotein; HDL= high-density lipoprotein; cholesterol ratio= total cholesterol/HDL; 
HbA1c= glycated hemoglobin; BP= blood pressure. 
*Since triglycerides was skewed, the P-value is by Mann-Whitney, a non-parametric test. The median and 
IQR (25
th
, 75
th
) for triglycerides in the Full sample is 116 (85, 158) mg/dL and in the Analytical sample is 
112 (87, 154) mg/dL. 
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Table 2. Univariate Analysis of All Complete Sleep Questionnaires (Full Sample) 
and Those Who Also Underwent Portable Sleep Study (Overnight Polygraphy; 
Analytical Sample)  
Sleep characteristics 
Full sample 
(n= 1,801) 
     Analytical 
       Sample 
       (n= 573) 
P-value 
AHI, events/h - 10 ±10              - 
ODI, events/h - 10 ±11              - 
Nadir SpO2, -           82 ±10 - 
Basal SpO2 -           95 ±5 - 
AHI ≥ 5, % - 58 - 
AHI ≥ 15, % - 18 - 
AHI ≥ 30, % - 5 - 
ESS continuous score 7 ±5            7±5 0.094 
ESS >10, % 30 34 0.009 
PSQI total score 5 ±3 5±3 0.095 
PSQI ≥ 5, % 46 50 0.018 
Sleep duration  
(self-reported) ≥ 6h,% 
94 93 0.180 
Sleep duration  
(self-reported),  min 
472 ±106 461 ±87 0.002 
Sleep efficiency, % 92 ±34 93 ±16 0.200 
Bed time  
(hours: minutes)* 
22:44 ±01:60 22:40 ± 01:40 <0.001 
Data are shown as mean ±SD for continuous and percentage for categorical variables. P-value is by 
independent t-test for continuous and normally distributed variables (the test is independent for each 
covariate) (P value indicates comparison of those included in analytic sample to those excluded) and by 
chi-square for categorical variables. OSA= obstructive sleep apnea; BMI= body mass index; AHI= apnea-
hypopnea index; ODI= oxygen desaturation index (with 4% drop in oxygen saturation); SpO2= oxygen 
saturation; AHI ≥5= mild OSA; AHI ≥15= moderate OSA; AHI ≥30= severe OSA; ESS= Epworth 
sleepiness scale; ESS >10= excessive daytime sleepiness; PSQI= Pittsburgh sleep quality index; PSQI 
≥5= poor sleep quality;  
*Bedtime = median and IQR 25
th
, 75
th
 (22:50 and 21:50, 23:50) for the full sample. Bedtime = median 
and IQR 25
th
, 75
th
 (22:50 and 21:50, 23:50) for the analytical sample. Bedtime was skewed, so P-value by 
Mann-Whitney, a non-parametric test. 
Those left blank were not measured by polygraphy. 
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Table 3. Multivariable Linear Regression Analysis Testing Association of CV Risk 
Factors (Outcome) and PSQI (main Predictor) 
 
PSQI total score PSQI <5 vs ≥ 5 
Outcome variable Beta Se P-value Beta se P-value 
VLDL-cholesterol, mg/dL 0.392 0.156 0.012 1.763 0.980 0.072 
ln Triglycerides, mg/dL 0.017 0.006 0.006 0.071 0.040 0.071 
HDL-cholesterol, mg/dL -0.194 0.155 0.208 -0.897 0.973 0.356 
LDL-cholesterol, mg/dL 0.082 0.500 0.870 1.886 3.120 0.546 
Total cholesterol, mg/dL 0.495 0.561 0.377 2.932 3.532 0.407 
Cholesterol ratio 0.033 0.017 0.060 0.195 0.110 0.077 
Glucose, mg/dL 0.180 0.247 0.468 -0.601 1.560 0.700 
HbA1c, % -0.015 0.009 0.102 -0.066 0.056 0.238 
Systolic BP, mmHg* 0.073 0.152 0.634 0.516 0.961 0.613 
Diastolic BP, mmHg* 0.060 0.116 0.602 0.290 0.731 0.693 
CV= cardiovascular; VLDL= very-low density lipoprotein; ln= natural logarithm transformation; HDL= 
high-density lipoprotein; LDL= low-density lipoprotein; cholesterol ratio= total cholesterol/HDL; 
HbA1c= glycated hemoglobin; BP= blood pressure; PSQI= Pittsburgh sleep quality index; PSQI ≥5= 
poor sleep quality; BMI= body mass index; ESS= Epworth sleepiness scale; OSA= obstructive sleep 
apnea; AHI= apnea hypopnea index (number of events per hour of sleep); se= standard error. Each line 
represents a unique regression model. Adjustments for age, sex (female= ref), race (White vs others), 
Wage categories (up to 5 MW vs >5MW and >5MW as ref), Education categories (illiterate vs high 
school vs technical/graduation and illiterate as ref), smoking status (never as ref), systolic BP, BMI, sleep 
duration (minutes); ESS continuous score, bedtime (in hours), and OSA by AHI continuous score. 
Missing data were excluded (all complete for regression analysis= 554). 
*not included systolic BP in adjustments. 
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Table 4. Restricted Analysis for those Without OSA (AHI<15), Testing the 
Association Between Lipid Components (Outcome) and Sleep Quality (n= 472) 
 
VLDL-cholesterol, mg/dL ln Triglycerides, mg/dL 
 Beta se P-value Beta se P-value 
PSQI 
total 
score 
0.446 0.170 0.009 0.018 0.007 0.010 
PSQI 
cutoff 5 
2.188 1.037 0.035 0.084 0.426 0.048 
OSA= obstructive sleep apnea; AHI= apnea hypopnea index; VLDL= very-low density lipoprotein 
cholesterol; ln= natural logarithm transformation; se= standard error; PSQI= Pittsburgh sleep quality 
index; PSQI ≥5= poor sleep quality; BMI= body mass index; ESS= Epworth sleepiness scale; BP= blood 
pressure. Adjustments: age, sex (female= ref), race (White vs others), Wage categories (up to 5 MW vs 
>5MW and >5MW as ref), Education categories (illiterate vs high school vs technical/graduation and 
illiterate as ref), smoking status (never as reference), BMI, ESS continuous score, sleep duration 
(minutes), bedtime (in hours), and daytime systolic BP. Missing data were excluded. All complete for 
regression analysis (n=423). 
 
 
 
Table 5. Restricted Analysis for those Without Lipid-lowering Medication (n= 510) 
Testing the Association Between Lipid Components (Outcome) and Sleep Quality  
 
VLDL-cholesterol, mg/dL ln Triglycerides, mg/dL 
 Beta se P-value Beta se P-value 
PSQI 
total 
score 
0.426 0.161 0.008 0.019 0.006 0.004 
PSQI 
cutoff 5 
1.681 1.013 0.097 0.080 0.040 0.047 
VLDL= very-low density lipoprotein cholesterol; ln= natural logarithm transformation; se= standard 
error; PSQI= Pittsburgh sleep quality index; PSQI ≥5= poor sleep quality; BMI= body mass index; ESS= 
Epworth sleepiness scale; BP= blood pressure, AHI= apnea hypopnea index. Adjustments: age, sex 
(female=ref), race (White vs others), Wage categories (up to 5 MW vs >5MW and >5MW as ref), 
Education categories (illiterate vs high school vs technical/graduation and illiterate as ref), smoking status 
(never as reference), BMI, ESS continuous score, sleep duration (minutes), bedtime (in hours), AHI, and 
daytime systolic BP. Missing data were excluded. All complete for regression analysis (n= 462). 
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